NCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
Clinical Trials
33 trialsNCT06654336 2026-03-13
RATIONAL
Ontario Clinical Oncology Group (OCOG)
Phase 2 Recruiting
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT06798558 2026-02-19
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Hackensack Meridian Health
Phase 2 Recruiting
NCT06470750 2026-01-20
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
Mayo Clinic
Recruiting
NCT05050084 2026-01-14
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Recruiting
NCT04384770 2025-12-22
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study
Jonsson Comprehensive Cancer Center
Active not recruiting
NCT04175431 2025-12-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
Phase 2 Recruiting
NCT05998278 2025-12-18
Personalized Optimization of Systematic Prostate Biopsy
Fujian Medical University Union Hospital
Phase NA Recruiting
NCT07251829 2025-11-26
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT03860961 2025-11-03
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
NRG Oncology
Phase NA Completed
NCT04286386 2025-10-27
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
M.D. Anderson Cancer Center
Active not recruiting
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT07210502 2025-10-07
LDR BURST
Royal Surrey County Hospital NHS Foundation Trust
Phase NA Not yet recruiting
NCT01352429 2025-07-17
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
Abramson Cancer Center at Penn Medicine
Active not recruiting
NCT04743934 2025-05-04
RAD 2003
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT03361735 2025-05-02
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05665738 2025-04-29
Two-fraction HDR Monotherapy for Localized Prostate Cancer
University of California, San Francisco
Phase NA Recruiting
NCT03654638 2025-04-04
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06044857 2025-03-12
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT02254746 2025-02-14
A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
Centre Hospitalier Universitaire Vaudois
Phase NA Completed
NCT06736054 2024-12-16
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Hoag Memorial Hospital Presbyterian
Phase 1 Recruiting
NCT03762759 2024-05-17
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Phase 2 Active not recruiting
NCT05919524 2023-09-26
SAFO
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Phase NA Unknown
NCT02624518 2023-04-10
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Stanford University
Phase 2/3 Completed
NCT02721979 2023-02-09
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
University of Washington
Phase 2 Terminated
NCT04020094 2021-09-22
AtezoVax
University of Utah
Phase 2 Withdrawn
NCT03829930 2021-08-02
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
George Washington University
Phase 1 Terminated
NCT02175212 2020-11-20
AADLPC
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Phase 3 Completed
NCT03780023 2020-10-28
CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients
University of California, Davis
Completed
NCT02168062 2020-07-23
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01219790 2016-04-19
GEMO
Institut Cancerologie de l'Ouest
Phase 1 Completed
NCT00183924 2014-05-22
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
University of Southern California
Phase 2 Completed